Guselkumab/Golimumab（JNJ-78934804）注射液

Guselkumab/Golimumab（JNJ-78934804）注射液的适应症是克罗恩病。 此药物由Janssen Research & Development, LLC/ 强生（中国）投资有限公司/ Cilag AG/ Janssen R&D, a Division of Janssen Pharmaceutica, NV; Cilag AG; Fisher Clinical Services; Fisher Clinical Services GmbH; Catalent Pharma Solutions; Catalent Germany Schorndorf GmbH; Catalent Pharma Solutions, LLC; Catalent CTS, LLC生产并提出实验申请，[实验的目的] 本研究的目的是评价JNJ-78934804注射液和古塞奇尤单抗和戈利木单抗相比在第48周的疗效